12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bedoradrine: Preliminary Phase IIb data

Preliminary data from 144 evaluable patients with acute exacerbations of asthma in the double-blind, U.S. Phase IIb MN-221-CL-007 trial showed that a 1-hour IV infusion with 1,200 µg MN-221 as an adjunct to standard of care (SOC) missed the primary endpoint of improving percent predicted FEV1 from baseline at 3 hours vs. placebo plus SOC. On secondary endpoints, MN-221 improved FEV1 area under the curve (AUC) from 0-1 hour (0.065 vs. 0.02 L, p=0.043), 0-2 hours (0.231 L vs....

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >